Volume 21, Number 12—December 2015
Dispatch
Factors Associated with Severe Leptospirosis, Martinique, 2010–2013
Patrick Hochedez
, Rafaelle Theodose, Claude Olive, Pascale Bourhy, Guillaume Hurtrel, Nicolas Vignier, Hossein Mehdaoui, Ruddy Valentino, Roland Martinez, Jean-Marie Delord, Cécile Herrmann, Isabelle Lamaury, Raymond Césaire, Mathieu Picardeau, and André Cabié
, Rafaelle Theodose, Claude Olive, Pascale Bourhy, Guillaume Hurtrel, Nicolas Vignier, Hossein Mehdaoui, Ruddy Valentino, Roland Martinez, Jean-Marie Delord, Cécile Herrmann, Isabelle Lamaury, Raymond Césaire, Mathieu Picardeau, and André Cabié
Table 2
Initial laboratory findings among 102 patients with quantitative PCR–confirmed leptospirosis, by disease severity, Martinique, 2010–2013
| Initial laboratory findings* | All patients, n = 102, no. (%) | Patients with severe disease, n = 12, no. (%) | Patients with nonsevere disease, n = 90, no. (%) | p value |
|---|---|---|---|---|
| Bilirubin | ||||
| μmol/L (Q1, Q3) | 20 (12, 49) | 56.5 (35.5, 103) | 18 (12, 38) | 0.0035 |
| >49 μmol/L, no./total (%) |
25/99 (25.2) |
7/12 (58.3) |
18/87 (20.7) |
0.01 |
| Creatinine | ||||
| μmol/L (Q1, Q3) | 104 (88, 154) | 169.5 (132.5, 217.5) | 100 (87, 137) | 0.0084 |
| >154 μmol/L, no./total (%) |
26/101 (25.7) |
7/12 (58.3) |
19/89 (21.3) |
0.011 |
| Urea nitrogen (mmo/Ll) | ||||
| mmol/L (Q1, Q3) | 5.7 (4.2, 9.3) | 10.1 (8, 18.5) | 5.5 (4, 8.6) | 0.0068 |
| >9.3, mmol/L, no./total (%) |
21/84 (25) |
4/8 (50) |
17/76 (22.4) |
0.103 |
| Creatine phosphokinase | ||||
| U/L (Q1, Q3) | 170 (70, 443) | 953 (204, 1332) | 145 (64, 390) | 0.0202 |
| >443 U/L, no./total (%) |
19/75 (25.3) |
5/9 (55.6) |
14/66 (21.2) |
0.041 |
| C-reactive protein | ||||
| mg/L (Q1, Q3) | 188.5 (108, 282) | 338.5 (197.5, 464.5) | 177.9 (89, 265) | 0.0017 |
| >282 mg/L, no./total (%) |
26/102 (25.5) |
7/12 (58.3) |
19/90 (21.1) |
0.011 |
| Potassium, mmol/ L (Q1, Q3) | 3.7 (3.4, 4.1) | 3.75 (3.35, 4.15) | 3.7 (3.3, 4.1) | 0.8 |
| Sodium, mmo/L (Q1, Q3) |
134 (132, 136) |
134 (131.5, 135) |
134 (132, 136) |
0.44 |
| Aspartate aminotransferase, U/L (Q1, Q3) | 61.5 (32, 102) | 73.5 (59, 126.5) | 57.5 (31, 102) | 0.19 |
| Alanine aminotransferase, U/L(Q1, Q3) |
55 (30, 96) |
49 (33.5, 74.5) |
55 (30, 99) |
0.69 |
| Hemoglobin | ||||
| g/dL (Q1, Q3) | 13.2 (12.2, 14.5) | 12.2 (11.6, 13) | 13.3 (12.4, 14.7) | 0.027 |
| <12.2 g/dL, no./total (%) |
26/102 (25.5) |
6/12 (50) |
20/90 (22.2) |
0.071 |
| Leukocytes, × 109 cells/L (Q1, Q3) |
8.51 (6.2, 10.9) |
10.3 (9.1, 11.4) |
7.8 (6.1, 10.5) |
0.07 |
| Lymphocytes | ||||
| × 109 cells/L (Q1, Q3) | 0.7 (0.49, 1) | 0.5 (0.2, 0.7) | 0.7 (0.5, 1) | 0.043 |
| <0.49 × 109 cells/L, no./total (%) |
24/92 (26) |
4/8 (50) |
20/84 (23.8) |
0.19 |
| Platelets | ||||
| Concentration, × 109/L (Q1, Q3) | 138 (92, 183) | 70.5 (32.5, 115) | 141 (99, 191) | 0.0011 |
| <92 × 109/L, no./total (%) |
26/101 (25.7) |
7/12 (58.3) |
19/89 (21.3) |
0.011 |
| Prothrombin time | ||||
| % (Q1, Q3) | 74 (68, 90.5) | 66.5 (56, 74.5) | 75.5 (69, 91) | 0.0166 |
| <68%, no./total (%) | 20/76 (26.3) | 7/12 (58.3) | 13/64 (20.3) | 0.011 |
*Continuous variables are summarized by using median, first quartile (Q1), and third quartile (Q3). Hematologic and biochemical variables are categorized into 2 groups, using Q1 or Q3 as appropriate.
Page created: November 17, 2015
Page updated: November 17, 2015
Page reviewed: November 17, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.